arrow
R

Robert H. Collins

university of texas system
H指数:54
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial

新诊断急性髓系白血病60岁及以上患者的分子特征分析:Beat AML临床试验报告

2025-04-030
OA
IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

IDH2突变与接受低强度治疗的新诊断急性髓系白血病老年患者的良好预后相关。

BLOOD
IF23.1
2024-11-051
PRE
Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

新诊断、老年急性髓系白血病患者在Venetoclax/阿扎胞苷时代的Beat AML主试验中的结局与生存情况

BLOOD
IF23.1
2024-11-050
PRE
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy

Beat-aml 2024 ELN-对新诊断AML的老年人进行低强度治疗的风险分层

2024-10-102
OAAI
Chronic Myeloid Leukemia, Version 2.2024

慢性粒细胞白血病2.2024版

2024-02-0116
OA
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML

评估enasidenib和适应风险的阿扎胞苷添加对新诊断的IDH2-mutant AML的疗效的研究

2024-01-127
OAAI
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
2023-05-258
OAAI
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

Entospletinib联合地西他滨治疗TP53突变或复杂核型的急性髓系白血病: Beat AML Master试验的2期子研究

CANCER
IF5.1
2023-04-207
PRE
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
2022-10-128
OAAI
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
2020-10-26111
OAAI
Telomere biology disorder prevalence and phenotypes in adults with familial hematologic and/or pulmonary presentations
2020-10-0926
OAAI
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
2019-01-16164
OAAI
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML

Ivosidenib在IDH1-Mutated复发或难治性AML中的持久缓解

2018-06-211.1K
OAAI